Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | Durvalumab & olaparib as maintenance in patients with MMR-proficient advanced endometrial cancer

Shannon N. Westin • 21 Oct 2023
ESMO 2023
Endometrial Cancer Antibodies Durvalumab Olaparib

Shannon N. Westin, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of durvalumab and olaparib as a maintenance therapy for patients with mismatch repair proficient advanced or recurrent endometrial cancer following the positive results of the Phase III DUO-E/GOG-3041/ENGOT-EN10 (NCT04269200) trial. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Shannon N. Westin

0:51
A novel ADC, AZD5335, for the treatment of solid tumors
Shannon N. Westin • 21 Oct 2023
0:54
Current and future areas of interest in the research of endometrial cancer
Shannon N. Westin • 21 Oct 2023
1:41
DUO-E/GOG-3041/ENGOT-EN10: durva + CP followed by mtx ± ola in first-line endometrial cancer
Shannon N. Westin • 21 Oct 2023

Related Videos

0:46
FRa expression and sequencing ADCs in endometrial cancer
Rebecca Porter • 8 Apr 2024
0:46
Antibody-drug conjugates in gynecological cancers
Rebecca Porter • 8 Apr 2024
0:56
Mirvetuximab soravtansine with pembrolizumab in MSS endometrial cancer
Rebecca Porter • 8 Apr 2024
1:08
Implications of phase III trials in endometrial cancer: dMMR patients and immunotherapy
Ritu Salani • 29 Feb 2024
The content of VJOncology is intended for healthcare professionals